Global Healthcare (02666)'s consolidated revenue for the first three quarters fell by about 5.8% year on year

Zhitong Finance App News, Global Healthcare (02666) announced that in the first three quarters of 2026, the Group will maintain its strategic strength under multiple pressures, advance financial business transformation in depth, steadily improve its medical service capabilities, and improve overall management steadily and steadily improve its quality. For the nine months ended September 30, 2026, the Group's consolidated revenue decreased by about 5.8% compared to the same period last year, mainly due to financial business transformation; profit for the period increased by about 0.2% compared to the same period last year, mainly due to the optimization of overall capital cost control and the reduction in costs related to the medical business; and the in-term profit of common stock holders increased by about 1.2% compared to the same period last year.

In terms of comprehensive medical business, the Group actively responded to health insurance payment reforms, continuously strengthened “integrated, differentiated, specialized, intelligent and lean” development, and continuously promoted capacity building such as “discipline construction, scientific research innovation, talent training, environment and service improvement”. The overall operation of subordinate medical institutions progressed steadily in the first three quarters of 2026: disciplinary capacity building achieved positive results, adding 4 provincial key specialties to 26, and adding 5 municipal key specialties to 117; vigorously developing outpatient treatment programs and non-medical insurance services, and further implementing holiday-free outpatient clinics, time-delayed outpatient clinics, expert outpatient clinics Clinic Outpatient emergency services reached 7.477 million, up 7.5% year on year, outpatient treatment revenue increased 3.5% year on year; solid promotion of special surgical operations, continuous optimization of surgical structures, increased the proportion of grade 3 and 4 surgeries by 2.4 percentage points; deepened standardized diagnosis and treatment of diseases, continued improvement of the business structure, increased the share of effective revenue by 2.3 percentage points year on year, and the resilience and sustainable development capacity of medical institutions was steadily enhanced.

In terms of specialty medicine and health technology, the Group “goes hand in hand” through contextual development and epitaxial expansion to cultivate characteristic businesses and core competencies. Currently, this section has made progress in layout expansion and capacity building. Among them, its subsidiary General Global Medical Technology Service (Tianjin) Co., Ltd. (“Global Technical Service”) became a member of the “Medical Device Blue Book: Report on the Development of China's Medical Device Industry (2026)” based on years of intensive practice; its “Innovative Practices and Initiatives for the Full-Cycle Management Model of Medical Equipment Assets” management case was successfully selected for the Blue Book practice section, further increasing its influence on the industry. In the first three quarters of 2026, GM Global Blue Bird Health Technology Co., Ltd. (Global Blue Bird) added 6 new offline medical care institutions, net increase of 746 nursing beds to 4,257, and built and operated 1,880 to 75,009 nursing beds. The business layout continued to expand. Furthermore, the Group continues to promote the health digital intelligence technology business. The digital intelligence project “Smart Hospital Platform Construction Based on Full-Scenario Full-Process AI Empowerment” won the first prize in the ICT China (2026) Case Selection hosted by the China Communications Enterprise Association, creating a replicable and promotable practical model for the digital transformation of central enterprise hospitals.

In terms of financial business, the Group continues to focus on business areas such as medical care, equipment manufacturing, chemicals and pharmaceuticals, and specialty industries, solidly advancing financial business transformation and upgrading planning and implementation, and actively developing new industry-finance models such as “leasing+equipment full-cycle management”, “leasing+supply chain finance”, and “leasing+technology introduction+operation” to serve the modern industrial system and the main business of central enterprises with the power of finance. In the first three quarters of 2026, investment in industrial projects such as equipment manufacturing, chemicals and pharmaceuticals increased significantly. The share of investment in service businesses increased from 12.8% in the same period last year to 44.0%, and the investment structure improved markedly. As of September 30, 2026, the Group's total interest-bearing assets declined slightly from the beginning of 2026. The net interest spread and net interest spread remained stable compared to the same period last year. The overall asset quality was stable and manageable, and provision coverage remained cautious.